Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1092-7. doi: 10.1016/j.ijrobp.2009.06.036. Epub 2009 Oct 30.
To evaluate dose-volume histograms (DVHs) of bladder and rectum from the use of cone beam CT (CBCT)-based three-dimensional (3D) treatment planning in intracavitary high-dose-rate brachytherapy (HDRB) for cervical cancer patients and to compare these parameters with International Commission on Radiation Units and Measurements (ICRU) of rectal and bladder reference point dose measurements.
Thirteen patients with cervical cancer underwent HDRB insertions. CT-compatible tandem and ovoid applicators were used to obtain intraoperative CBCT images. The use of a rectal tube and injection of bladder contrast before scanning facilitated contouring the rectum and bladder. All patients underwent intraoperative orthogonal x-ray filming, and treatments were prescribed using standard two-dimensional planning and dosimetry. DVHs for the bladder and rectum were constructed for each treatment. The minimum dose in the most irradiated 2.0-cm(3) volume of bladder (B(D2V)) and rectum (R(D2V)) were determined from DVHs and compared to ICRU reference point estimates of bladder (B(ICRU)) and rectum (R(ICRU)) doses.
Twenty-six CBCT-based plans were evaluated. The median B(ICRU) dose (347 cGy; range, 164-601 cGy) was significantly lower (p < 0.001) than the median B(D2V) (594 cGy; range, 260-969 cGy). The median R(ICRU) dose (405 cGy; range, 189-700 cGy) was also significantly lower (p = 0.037) than the median R(D2V) (488 cGy; range, 227-786 cGy).
CBCT-based 3D planning can be used in HDRB for cervical cancer and is a convenient alternative to CT-based planning, with the advantage of minimizing applicator motion. Correlation with late effects will further define the role of CBCT-based 3D dosimetry in HDRB planning.
评估使用基于锥形束 CT(CBCT)的三维(3D)治疗计划在宫颈癌腔内高剂量率近距离放疗(HDRB)中的膀胱和直肠剂量-体积直方图(DVHs),并将这些参数与国际辐射单位和测量委员会(ICRU)对直肠和膀胱参考点剂量测量的结果进行比较。
13 例宫颈癌患者接受 HDRB 插入治疗。使用 CT 兼容的尾管和卵圆型施源器获取术中 CBCT 图像。在扫描前使用直肠管和膀胱造影剂来辅助直肠和膀胱的勾画。所有患者均接受术中正交 X 射线拍摄,并且使用标准二维计划和剂量学来制定治疗方案。为每个治疗方案构建膀胱和直肠的 DVHs。从 DVHs 中确定膀胱(B(D2V))和直肠(R(D2V))中受照 2.0cm3 体积的最小剂量,并将其与 ICRU 参考点估计的膀胱(B(ICRU))和直肠(R(ICRU))剂量进行比较。
评估了 26 个基于 CBCT 的计划。ICRU 参考点膀胱剂量(347cGy;范围,164-601cGy)中位数明显低于(p<0.001)膀胱 D2V 体积剂量(594cGy;范围,260-969cGy)中位数。ICRU 参考点直肠剂量(405cGy;范围,189-700cGy)中位数也明显低于(p=0.037)直肠 D2V 体积剂量(488cGy;范围,227-786cGy)中位数。
基于 CBCT 的 3D 计划可用于宫颈癌 HDRB,是 CT 基于计划的便捷替代方案,其优势在于可最大限度地减少施源器运动。与晚期效应的相关性将进一步确定基于 CBCT 的 3D 剂量学在 HDRB 计划中的作用。